Heart failure clue: blood test may forecast therapy success
NCT ID NCT07469137
First seen Mar 14, 2026 · Last updated Jun 12, 2026 · Updated 12 times
Summary
This study looks at whether a substance called YKL-40 in the blood can help predict how well heart failure patients will respond to cardiac resynchronization therapy (CRT), a special pacemaker. About 51 adults with severe heart failure will have blood samples taken during their routine CRT procedure. Researchers will then check their heart function 6 months later to see if YKL-40 levels are linked to improvement. The goal is to find a simple way to identify who will benefit most from CRT.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC RESYNCHRONISATION THERAPY (CRT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Trakya University
Edirne, Edirne, Turkey (Türkiye)
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.